Substance Use in Women Research Report

  1. Office of Research on Women’s Health (ORWH). How Sex and Gender Influence Health and Disease [Infographic].; n.d.
  2. Institute of Medicine (US) Committee on Understanding the Biology of Sex and Gender Differences. Exploring the Biological Contributions to Human Health: Does Sex Matter? (Wizemann TM, Pardue M-L, eds.). Washington (DC): National Academies Press (US); 2001. Accessed January 3, 2018.
  3. Eggert J, Theobald H, Engfeldt P. Effects of alcohol consumption on female fertility during an 18-year period. Fertil Steril. 2004;81(2):379-383. doi:10.1016/j.fertnstert.2003.06.018
  4. Joesoef MR, Beral V, Aral SO, Rolfs RT, Cramer DW. Fertility and use of cigarettes, alcohol, marijuana, and cocaine. Ann Epidemiol. 1993;3(6):592-594.
  5. Tolstrup JS, Kjaer SK, Holst C, et al. Alcohol use as predictor for infertility in a representative population of Danish women. Acta Obstet Gynecol Scand. 2003;82(8):744-749.
  6. Schoenbaum EE, Hartel D, Lo Y, et al. HIV infection, drug use, and onset of natural menopause. Clin Infect Dis Off Publ Infect Dis Soc Am. 2005;41(10):1517-1524. doi:10.1086/497270
  7. Center for Substance Abuse Treatment. Substance Abuse: Clinical Issues in Intensive Outpatient Treatment. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2006. Accessed January 19, 2018.
  8. Daley M, Argeriou M, McCarty D, Callahan JJ, Shepard DS, Williams CN. The impact of substance abuse treatment modality on birth weight and health care expenditures. J Psychoactive Drugs. 2001;33(1):57-66. doi:10.1080/02791072.2001.10400469
  9. Svikis DS, Golden AS, Huggins GR, et al. Cost-effectiveness of treatment for drug-abusing pregnant women. Drug Alcohol Depend. 1997;45(1-2):105-113.
  10. Substance Abuse and Mental Health Services Administration (SAMHSA). Addressing the Needs of Women and Girls: Core Competencies for Mental Health and Substance Abuse Service Professionals. Published October 1, 2011. Accessed January 3, 2018.
  11. National Institutes of Health (NIH). Amendment: NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research.; 2001.
  12. Clayton JA, Collins FS. Policy: NIH to balance sex in cell and animal studies. Nature. 2014;509(7500):282-283.
  13. Center for Behavioral Health Statistics and Quality. Results from the 2016 National Survey on Drug Use and Health: Detailed Tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2017. Accessed November 7, 2017.
  14. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS): 2004-2014. National Admissions to Substance Abuse Treatment Services. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016.
  15. Anthony JC, Warner LA, Kessler RC. Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol. 1994;2(3):244-268. doi:10.1037/1064-1297.2.3.244
  16. Robbins SJ, Ehrman RN, Childress AR, O’Brien CP. Comparing levels of cocaine cue reactivity in male and female outpatients. Drug Alcohol Depend. 1999;53(3):223-230.
  17. Hitschfeld MJ, Schneekloth TD, Ebbert JO, et al. Female smokers have the highest alcohol craving in a residential alcoholism treatment cohort. Drug Alcohol Depend. 2015;150:179-182. doi:10.1016/j.drugalcdep.2015.02.016
  18. Fox HC, Morgan PT, Sinha R. Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2014;39(6):1527-1537. doi:10.1038/npp.2014.1
  19. Kennedy AP, Epstein DH, Phillips KA, Preston KL. Sex differences in cocaine/heroin users: drug-use triggers and craving in daily life. Drug Alcohol Depend. 2013;132(1-2):29-37. doi:10.1016/j.drugalcdep.2012.12.025
  20. Kippin TE, Fuchs RA, Mehta RH, et al. Potentiation of cocaine-primed reinstatement of drug seeking in female rats during estrus. Psychopharmacology (Berl). 2005;182(2):245-252. doi:10.1007/s00213-005-0071-y
  21. Rubonis AV, Colby SM, Monti PM, Rohsenow DJ, Gulliver SB, Sirota AD. Alcohol cue reactivity and mood induction in male and female alcoholics. J Stud Alcohol. 1994;55(4):487-494.
  22. Makela P, Wakeley J, Gijsman H, Robson PJ, Bhagwagar Z, Rogers RD. Low doses of delta-9 tetrahydrocannabinol (THC) have divergent effects on short-term spatial memory in young, healthy adults. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2006;31(2):462-470. doi:10.1038/sj.npp.1300871
  23. Pope HG, Jacobs A, Mialet JP, Yurgelun-Todd D, Gruber S. Evidence for a sex-specific residual effect of cannabis on visuospatial memory. Psychother Psychosom. 1997;66(4):179-184.
  24. Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2007;32(6):1391-1403. doi:10.1038/sj.npp.1301243
  25. Penetar DM, Kouri EM, McCarthy EM, et al. Nicotine Pretreatment Increases Dysphoric Effects of Alcohol in Luteal-Phase Female Volunteers. Int J Environ Res Public Health. 2009;6(2):526-546. doi:10.3390/ijerph6020526
  26. Butters JE. Promoting Healthy Choices: The Importance of Differentiating Between Ordinary and High Risk Cannabis Use Among High-School Students. Subst Use Misuse. 2005;40(6):845-855. doi:10.1081/JA-200030803
  27. Medina KL, McQueeny T, Nagel BJ, Hanson KL, Yang TT, Tapert SF. Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects. Addict Biol. 2009;14(4):457-468. doi:10.1111/j.1369-1600.2009.00166.x
  28. McQueeny T, Padula CB, Price J, Medina KL, Logan P, Tapert SF. Gender effects on amygdala morphometry in adolescent marijuana users. Behav Brain Res. 2011;224(1):128-134. doi:10.1016/j.bbr.2011.05.031
  29. Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W. Cannabinoid self-administration in rats: sex differences and the influence of ovarian function. Br J Pharmacol. 2007;152(5):795-804. doi:10.1038/sj.bjp.0707465
  30. Craft RM, Marusich JA, Wiley JL. Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci. 2013;92(8-9):476-481. doi:10.1016/j.lfs.2012.06.009
  31. Craft RM, Wakley AA, Tsutsui KT, Laggart JD. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat. J Pharmacol Exp Ther. 2012;340(3):787-800. doi:10.1124/jpet.111.188540
  32. Romero EM, Fernández B, Sagredo O, et al. Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Brain Res Dev Brain Res. 2002;136(2):85-92.
  33. Tseng AH, Craft RM. Sex differences in antinociceptive and motoric effects of cannabinoids. Eur J Pharmacol. 2001;430(1):41-47.
  34. Wiley JL. Sex-dependent effects of Δ9-tetrahydrocannabinol on locomotor activity in mice. Neurosci Lett. 2003;352(2):77-80. doi:10.1016/j.neulet.2003.08.050
  35. Craft R, Leitl M. Gonadal hormone modulation of the behavioral effects of Δ9-tetrahydrocannabinol in male and female rats. Eur J Pharmacol. 2008;578:37-42. doi:10.1016/j.ejphar.2007.09.004
  36. Fattore L, Spano M, Altea S, Fadda P, Fratta W. Drug- and cue-induced reinstatement of cannabinoid-seeking behaviour in male and female rats: influence of ovarian hormones. Br J Pharmacol. 2010;160(3):724-735. doi:10.1111/j.1476-5381.2010.00734.x
  37. Winsauer PJ, Daniel JM, Filipeanu CM, et al. Long-term behavioral and pharmacodynamic effects of delta-9-tetrahydrocannabinol in female rats depend on ovarian hormone status. Addict Biol. 2011;16(1):64-81.
  38. Krebs-Kraft DL, Hill MN, Hillard CJ, McCarthy MM. Sex difference in cell proliferation in developing rat amygdala mediated by endocannabinoids has implications for social behavior. Proc Natl Acad Sci U S A. 2010;107(47):20535-20540. doi:10.1073/pnas.1005003107
  39. Thomas H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend. 1996;42(3):201-207.
  40. Buckner JD, Heimberg RG, Schneier FR, Liu S-M, Wang S, Blanco C. The relationship between cannabis use disorders and social anxiety disorder in the National Epidemiological Study of Alcohol and Related Conditions (NESARC). Drug Alcohol Depend. 2012;124(1-2):128-134. doi:10.1016/j.drugalcdep.2011.12.023
  41. Buckner JD, Mallott MA, Schmidt NB, Taylor J. Peer influence and gender differences in problematic cannabis use among individuals with social anxiety. J Anxiety Disord. 2006;20(8):1087-1102. doi:10.1016/j.janxdis.2006.03.002
  42. Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis- and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004;74(3):265-272. doi:10.1016/j.drugalcdep.2004.02.001
  43. Khan SS, Secades-Villa R, Okuda M, et al. Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions. Drug Alcohol Depend. 2013;130(1-3):101-108. doi:10.1016/j.drugalcdep.2012.10.015
  44. Evans SM, Foltin RW. Exogenous progesterone attenuates the subjective effects of smoked cocaine in women, but not in men. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2006;31(3):659-674. doi:10.1038/sj.npp.1300887
  45. Justice AJ, De Wit H. Acute effects of d-amphetamine during the early and late follicular phases of the menstrual cycle in women. Pharmacol Biochem Behav. 2000;66(3):509-515.
  46. Justice AJ, de Wit H. Acute effects of d-amphetamine during the follicular and luteal phases of the menstrual cycle in women. Psychopharmacology (Berl). 1999;145(1):67-75.
  47. Anker JJ, Carroll ME. Females are more vulnerable to drug abuse than males: evidence from preclinical studies and the role of ovarian hormones. Curr Top Behav Neurosci. 2011;8:73-96. doi:10.1007/7854_2010_93
  48. NIDA Notes: Gender Differences in Drug Abuse Risks and Treatment. Published September 1, 2000. Accessed January 26, 2018.
  49. Cretzmeyer M, Sarrazin MV, Huber DL, Block RI, Hall JA. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat. 2003;24(3):267-277.
  50. Brecht M-L, O’Brien A, von Mayrhauser C, Anglin MD. Methamphetamine use behaviors and gender differences. Addict Behav. 2004;29(1):89-106.
  51. Hser Y-I, Evans E, Huang Y-C. Treatment outcomes among women and men methamphetamine abusers in California. J Subst Abuse Treat. 2005;28(1):77-85. doi:10.1016/j.jsat.2004.10.009
  52. Zweben JE, Cohen JB, Christian D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict. 2004;13(2):181-190. doi:10.1080/10550490490436055
  53. Rawson RA, Gonzales R, Obert JL, McCann MJ, Brethen P. Methamphetamine use among treatment-seeking adolescents in Southern California: participant characteristics and treatment response. J Subst Abuse Treat. 2005;29(2):67-74. doi:10.1016/j.jsat.2005.04.001
  54. Dluzen DE, Liu B. Gender differences in methamphetamine use and responses: a review. Gend Med. 2008;5(1):24-35.
  55. Kim JYS, Fendrich M. Gender differences in juvenile arrestees’ drug use, self-reported dependence, and perceived need for treatment. Psychiatr Serv Wash DC. 2002;53(1):70-75. doi:10.1176/
  56. Lin S-K, Ball D, Hsiao C-C, Chiang Y-L, Ree S-C, Chen C-K. Psychiatric comorbidity and gender differences of persons incarcerated for methamphetamine abuse in Taiwan. Psychiatry Clin Neurosci. 2004;58(2):206-212.
  57. Liechti ME, Gamma A, Vollenweider FX. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl). 2001;154(2):161-168.
  58. Verheyden SL, Hadfield J, Calin T, Curran HV. Sub-acute effects of MDMA (+/-3,4-methylenedioxymethamphetamine, “ecstasy”) on mood: evidence of gender differences. Psychopharmacology (Berl). 2002;161(1):23-31. doi:10.1007/s00213-001-0995-9
  59. Hoshi R, Pratt H, Mehta S, Bond AJ, Curran HV. An investigation into the sub-acute effects of ecstasy on aggressive interpretative bias and aggressive mood - are there gender differences? J Psychopharmacol Oxf Engl. 2006;20(2):291-301. doi:10.1177/0269881106060505
  60. Campbell GA, Rosner MH. The agony of ecstasy: MDMA (3,4-methylenedioxymethamphetamine) and the kidney. Clin J Am Soc Nephrol CJASN. 2008;3(6):1852-1860. doi:10.2215/CJN.02080508
  61. Moritz ML, Kalantar-Zadeh K, Ayus JC. Ecstacy-associated hyponatremia: why are women at risk? Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2013;28(9):2206-2209. doi:10.1093/ndt/gft192
  62. MDMA can be fatal in warm environments [news release]. National Institute on Drug Abuse. Published June 3, 2014. Accessed January 4, 2018.
  63. Powis B, Griffiths P, Gossop M, Strang J. The differences between male and female drug users: community samples of heroin and cocaine users compared. Subst Use Misuse. 1996;31(5):529-543.
  64. Bryant J, Brener L, Hull P, Treloar C. Needle sharing in regular sexual relationships: an examination of serodiscordance, drug using practices, and the gendered character of injecting. Drug Alcohol Depend. 2010;107(2-3):182-187. doi:10.1016/j.drugalcdep.2009.10.007
  65. Lum PJ, Sears C, Guydish J. Injection risk behavior among women syringe exchangers in San Francisco. Subst Use Misuse. 2005;40(11):1681-1696. doi:10.1080/10826080500222834
  66. Dwyer R, Richardson D, Ross MW, Wodak A, Miller ME, Gold J. A comparison of HIV risk between women and men who inject drugs. AIDS Educ Prev Off Publ Int Soc AIDS Educ. 1994;6(5):379-389.
  67. Gjersing L, Bretteville-Jensen AL. Gender differences in mortality and risk factors in a 13-year cohort study of street-recruited injecting drug users. BMC Public Health. 2014;14:440. doi:10.1186/1471-2458-14-440
  68. Riley JL, Robinson ME, Wise EA, Myers CD, Fillingim RB. Sex differences in the perception of noxious experimental stimuli: a meta-analysis. Pain. 1998;74(2-3):181-187.
  69. Gerdle B, Björk J, Cöster L, Henriksson K, Henriksson C, Bengtsson A. Prevalence of widespread pain and associations with work status: a population study. BMC Musculoskelet Disord. 2008;9:102. doi:10.1186/1471-2474-9-102
  70. Ailes EC, Dawson AL, Lind JN, et al. Opioid prescription claims among women of reproductive age--United States, 2008-2012. MMWR Morb Mortal Wkly Rep. 2015;64(2):37-41.
  71. McHugh RK, Devito EE, Dodd D, et al. Gender differences in a clinical trial for prescription opioid dependence. J Subst Abuse Treat. 2013;45(1):38-43. doi:10.1016/j.jsat.2012.12.007
  72. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. Multiple Cause of Death, 1999-2016 on CDC WONDER Online Database, released 2017. Data are from the Multiple Cause of Death Files, 1999-2016, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Published 2017. Accessed February 14, 2018.
  73. CDC Vital Signs: Prescription Painkiller Overdoses infographic. Published November 8, 2017. Accessed January 31, 2018.
  74. National Institute of Mental Health (NIMH). Anxiety Disorders. Published 2016. Accessed January 5, 2018.
  75. National Institute of Mental Health (NIMH). Women and Depression: Discovering Hope. Bethesda, MD: National Institutes of Health
  76. National Heart, Lung, and Blood Institute (NHLBI). Problem Sleepiness in Your Patient. NIH Publication No. 97-4073. Bethesda, MD: National Institutes of Health; 2017.
  77. Holman CD, English DR, Milne E, Winter MG. Meta-analysis of alcohol and all-cause mortality: a validation of NHMRC recommendations. Med J Aust. 1996;164(3):141-145.
  78. Piazza NJ, Vrbka JL, Yeager RD. Telescoping of alcoholism in women alcoholics. Int J Addict. 1989;24(1):19-28.
  79. National Institute on Alcohol Abuse and Alcoholism. Alcohol: A Women’s Health Issue. Bethesda, MD: National Institutes of Health; 2003.
  80. Rehm J, Shield KD, Joharchi N, Shuper PA. Alcohol consumption and the intention to engage in unprotected sex: systematic review and meta-analysis of experimental studies. Addict Abingdon Engl. 2012;107(1):51-59. doi:10.1111/j.1360-0443.2011.03621.x
  81. Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N Engl J Med. 1990;322(2):95-99. doi:10.1056/NEJM199001113220205
  82. National Institute on Alcohol Abuse and Alcoholism (NIAAA). Alcohol Alert: Are Women More Vulnerable to Alcohol’s Effects? Rockville, MD; 1999. Accessed January 5, 2018.
  83. Lieber CS. Ethnic and gender differences in ethanol metabolism. Alcohol Clin Exp Res. 2000;24(4):417-418.
  84. Melikian AA, Djordjevic MV, Hosey J, et al. Gender differences relative to smoking behavior and emissions of toxins from mainstream cigarette smoke. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2007;9(3):377-387. doi:10.1080/14622200701188836
  85. Cosgrove KP, Wang S, Kim S-J, et al. Sex differences in the brain’s dopamine signature of cigarette smoking. J Neurosci Off J Soc Neurosci. 2014;34(50):16851-16855. doi:10.1523/JNEUROSCI.3661-14.2014
  86. Torres OV, O’Dell LE. Stress is a principal factor that promotes tobacco use in females. Prog Neuropsychopharmacol Biol Psychiatry. 2016;65:260-268. doi:10.1016/j.pnpbp.2015.04.005
  87. Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med. 2013;368(4):351-364. doi:10.1056/NEJMsa1211127
  88. National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014.
  89. Farley TM, Meirik O, Chang CL, Poulter NR. Combined oral contraceptives, smoking, and cardiovascular risk. J Epidemiol Community Health. 1998;52(12):775-785.
  90. Piper ME, Cook JW, Schlam TR, et al. Gender, race, and education differences in abstinence rates among participants in two randomized smoking cessation trials. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2010;12(6):647-657. doi:10.1093/ntr/ntq067
  91. Jones HE, Fielder A. Neonatal abstinence syndrome: Historical perspective, current focus, future directions. Prev Med. 2015;80:12-17. doi:10.1016/j.ypmed.2015.07.017
  92. Tobacco, drug use in pregnancy can double risk of stillbirth. Eunice Kennedy Shriver National Institute of Child Health and Human Development. Published December 11, 2013. Accessed January 31, 2018.
  93. Wendell AD. Overview and epidemiology of substance abuse in pregnancy. Clin Obstet Gynecol. 2013;56(1):91-96. doi:10.1097/GRF.0b013e31827feeb9
  94. Hudak ML, Tan RC, COMMITTEE ON DRUGS, COMMITTEE ON FETUS AND NEWBORN, American Academy of Pediatrics. Neonatal drug withdrawal. Pediatrics. 2012;129(2):e540-560. doi:10.1542/peds.2011-3212
  95. MedlinePlus, U.S. National Library of Medicine. Neonatal abstinence syndrome: MedlinePlus Medical Encyclopedia. Published December 21, 2017. Accessed January 12, 2018.
  96. Martin CE, Longinaker N, Mark K, Chisolm MS, Terplan M. Recent trends in treatment admissions for marijuana use during pregnancy. J Addict Med. 2015;9(2):99-104. doi:10.1097/ADM.0000000000000095
  97. Young-Wolff KC, Tucker L-Y, Alexeeff S, et al. Trends in Self-reported and Biochemically Tested Marijuana Use Among Pregnant Females in California From 2009-2016. JAMA. 2017;318(24):2490. doi:10.1001/jama.2017.17225
  98. Kline J, Hutzler M, Levin B, Stein Z, Susser M, Warburton D. Marijuana and spontaneous abortion of known karyotype. Paediatr Perinat Epidemiol. 1991;5(3):320-332.
  99. Wilcox AJ, Weinberg CR, Baird DD. Risk factors for early pregnancy loss. Epidemiol Camb Mass. 1990;1(5):382-385.
  100. Asch RH, Smith CG. Effects of delta 9-THC, the principal psychoactive component of marijuana, during pregnancy in the rhesus monkey. J Reprod Med. 1986;31(12):1071-1081.
  101. Campolongo P, Trezza V, Ratano P, Palmery M, Cuomo V. Developmental consequences of perinatal cannabis exposure: behavioral and neuroendocrine effects in adult rodents. Psychopharmacology (Berl). 2011;214(1):5-15. doi:10.1007/s00213-010-1892-x
  102. Fried PA, Watkinson B, Gray R. A follow-up study of attentional behavior in 6-year-old children exposed prenatally to marihuana, cigarettes, and alcohol. Neurotoxicol Teratol. 1992;14(5):299-311.
  103. Goldschmidt L, Day NL, Richardson GA. Effects of prenatal marijuana exposure on child behavior problems at age 10. Neurotoxicol Teratol. 2000;22(3):325-336.
  104. Fried PA, Smith AM. A literature review of the consequences of prenatal marihuana exposure. An emerging theme of a deficiency in aspects of executive function. Neurotoxicol Teratol. 2001;23(1):1-11.
  105. National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
  106. Frank DA, Bauchner H, Parker S, et al. Neonatal body proportionality and body composition after in utero exposure to cocaine and marijuana. J Pediatr. 1990;117(4):622-626.
  107. Mark K, Desai A, Terplan M. Marijuana use and pregnancy: prevalence, associated characteristics, and birth outcomes. Arch Womens Ment Health. 2016;19(1):105-111. doi:10.1007/s00737-015-0529-9
  108. Shiono PH, Klebanoff MA, Nugent RP, et al. The impact of cocaine and marijuana use on low birth weight and preterm birth: a multicenter study. Am J Obstet Gynecol. 1995;172(1 Pt 1):19-27.
  109. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. Committee Opinion No. 637: Marijuana Use During Pregnancy and Lactation. Obstet Gynecol. 2015;126(1):234-238. doi:10.1097/01.AOG.0000467192.89321.a6
  110. Roberson EK, Patrick WK, Hurwitz EL. Marijuana use and maternal experiences of severe nausea during pregnancy in Hawai’i. Hawaii J Med Public Health J Asia Pac Med Public Health. 2014;73(9):283-287.
  111. Westfall RE, Janssen PA, Lucas P, Capler R. Survey of medicinal cannabis use among childbearing women: patterns of its use in pregnancy and retroactive self-assessment of its efficacy against “morning sickness.” Complement Ther Clin Pract. 2006;12(1):27-33. doi:10.1016/j.ctcp.2005.09.006
  112. Trezza V, Campolongo P, Cassano T, et al. Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats. Psychopharmacology (Berl). 2008;198(4):529-537. doi:10.1007/s00213-008-1162-3
  113. Antonelli T, Tomasini MC, Tattoli M, et al. Prenatal exposure to the CB1 receptor agonist WIN 55,212-2 causes learning disruption associated with impaired cortical NMDA receptor function and emotional reactivity changes in rat offspring. Cereb Cortex N Y N 1991. 2005;15(12):2013-2020. doi:10.1093/cercor/bhi076
  114. Mereu G, Fà M, Ferraro L, et al. Prenatal exposure to a cannabinoid agonist produces memory deficits linked to dysfunction in hippocampal long-term potentiation and glutamate release. Proc Natl Acad Sci U S A. 2003;100(8):4915-4920. doi:10.1073/pnas.0537849100
  115. Fried PA, Makin JE. Neonatal behavioural correlates of prenatal exposure to marihuana, cigarettes and alcohol in a low risk population. Neurotoxicol Teratol. 1987;9(1):1-7.
  116. de Moraes Barros MC, Guinsburg R, Mitsuhiro S, Chalem E, Laranjeira RR. Neurobehavioral profile of healthy full-term newborn infants of adolescent mothers. Early Hum Dev. 2008;84(5):281-287. doi:10.1016/j.earlhumdev.2007.07.001
  117. Richardson GA, Ryan C, Willford J, Day NL, Goldschmidt L. Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years. Neurotoxicol Teratol. 2002;24(3):309-320.
  118. Schempf AH, Strobino DM. Illicit Drug Use and Adverse Birth Outcomes: Is It Drugs or Context? J Urban Health Bull N Y Acad Med. 2008;85(6):858-873. doi:10.1007/s11524-008-9315-6
  119. Sonon KE, Richardson GA, Cornelius JR, Kim KH, Day NL. Prenatal marijuana exposure predicts marijuana use in young adulthood. Neurotoxicol Teratol. 2015;47:10-15. doi:10.1016/
  120. Perez-Reyes M, Wall ME. Presence of delta9-tetrahydrocannabinol in human milk. N Engl J Med. 1982;307(13):819-820. doi:10.1056/NEJM198209233071311
  121. Astley SJ, Little RE. Maternal marijuana use during lactation and infant development at one year. Neurotoxicol Teratol. 1990;12(2):161-168.
  122. Djulus J, Moretti M, Koren G. Marijuana use and breastfeeding. Can Fam Physician Médecin Fam Can. 2005;51:349-350.
  123. Cain MA, Bornick P, Whiteman V. The maternal, fetal, and neonatal effects of cocaine exposure in pregnancy. Clin Obstet Gynecol. 2013;56(1):124-132. doi:10.1097/GRF.0b013e31827ae167
  124. Bauer CR, Langer JC, Shankaran S, et al. Acute neonatal effects of cocaine exposure during pregnancy. Arch Pediatr Adolesc Med. 2005;159(9):824-834. doi:10.1001/archpedi.159.9.824
  125. Chasnoff IJ, Bussey ME, Savich R, Stack CM. Perinatal cerebral infarction and maternal cocaine use. J Pediatr. 1986;108(3):456-459.
  126. Eyler FD, Behnke M, Garvan CW, Woods NS, Wobie K, Conlon M. Newborn evaluations of toxicity and withdrawal related to prenatal cocaine exposure. Neurotoxicol Teratol. 2001;23(5):399-411.
  127. Gorman MC, Orme KS, Nguyen NT, Kent EJ, Caughey AB. Outcomes in pregnancies complicated by methamphetamine use. Am J Obstet Gynecol. 2014;211(4):429.e1-7. doi:10.1016/j.ajog.2014.06.005
  128. Smith LM, LaGasse LL, Derauf C, et al. The infant development, environment, and lifestyle study: effects of prenatal methamphetamine exposure, polydrug exposure, and poverty on intrauterine growth. Pediatrics. 2006;118(3):1149-1156. doi:10.1542/peds.2005-2564
  129. Diaz SD, Smith LM, LaGasse LL, et al. Effects of prenatal methamphetamine exposure on behavioral and cognitive findings at 7.5 years of age. J Pediatr. 2014;164(6):1333-1338. doi:10.1016/j.jpeds.2014.01.053
  130. LaGasse LL, Derauf C, Smith LM, et al. Prenatal Methamphetamine Exposure and Childhood Behavior Problems at 3 and 5 Years of Age. Pediatrics. 2012;129(4):681-688. doi:10.1542/peds.2011-2209
  131. Schaefer TL, Grace CE, Braun AA, et al. Cognitive impairments from developmental exposure to serotonergic drugs: citalopram and MDMA. Int J Neuropsychopharmacol Off Sci J Coll Int Neuropsychopharmacol CINP. 2013;16(6):1383-1394. doi:10.1017/S1461145712001447
  132. Singer LT, Moore DG, Min MO, et al. One-year outcomes of prenatal exposure to MDMA and other recreational drugs. Pediatrics. 2012;130(3):407-413. doi:10.1542/peds.2012-0666
  133. Singer LT, Moore DG, Min MO, et al. Motor delays in MDMA (ecstasy) exposed infants persist to 2 years. Neurotoxicol Teratol. 2016;54:22-28. doi:10.1016/
  134. Bandstra ES, Morrow CE, Mansoor E, Accornero VH. Prenatal drug exposure: infant and toddler outcomes. J Addict Dis. 2010;29(2):245-258. doi:10.1080/10550881003684871
  135. Centers for Disease Control and Prevention (CDC). Reproductive Health: Pregnancy Complications. Published June 17, 2016. Accessed February 5, 2018.
  136. Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol. 2011;205(1):51.e1-8. doi:10.1016/j.ajog.2011.02.029
  137. Food and Drug Administration (FDA). Labeling - Pregnancy and Lactation Labeling (Drugs) Final Rule. Published December 3, 2014. Accessed January 16, 2018.
  138. Adam MP, Polifka JE, Friedman JM. Evolving knowledge of the teratogenicity of medications in human pregnancy. Am J Med Genet C Semin Med Genet. 2011;157C(3):175-182. doi:10.1002/ajmg.c.30313
  139. Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant outcomes. Pediatrics. 2015;135(5):842-850. doi:10.1542/peds.2014-3299
  140. Centers for Disease Control and Prevention (CDC). Medications and Pregnancy. Centers for Disease Control and Prevention. Published September 14, 2017. Accessed January 16, 2018.
  141. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776-789.
  142. American Academy of Pediatrics. Ages and Stages: Medication Safety Tips for the Breastfeeding Mom. Accessed January 17, 2018.
  143. Julie Mennnella. Alcohol’s Effect on Lactation. National Institute on Alcohol Abuse and Alcoholism (NIAAA) Accessed January 17, 2018.
  144. American Academy of Pediatrics. Breastfeeding and the use of human milk. Pediatrics. 2012;129(3):e827-841. doi:10.1542/peds.2011-3552
  145. Wickström R. Effects of nicotine during pregnancy: human and experimental evidence. Curr Neuropharmacol. 2007;5(3):213-222. doi:10.2174/157015907781695955
  146. Centers for Disease Control and Prevention (CDC). Reproductive Health: Tobacco Use and Pregnancy. Published September 29, 2017. Accessed January 17, 2018.
  147. Rydell M, Magnusson C, Cnattingius S, Granath F, Svensson AC, Galanti MR. Exposure to maternal smoking during pregnancy as a risk factor for tobacco use in adult offspring. Am J Epidemiol. 2014;179(12):1409-1417. doi:10.1093/aje/kwu074
  148. Khader YS, Al-Akour N, Alzubi IM, Lataifeh I. The association between second hand smoke and low birth weight and preterm delivery. Matern Child Health J. 2011;15(4):453-459. doi:10.1007/s10995-010-0599-2
  149. National Institute on Drug Abuse (NIDA). NIH study examines nicotine as a gateway drug [news release]. Published November 2, 2011. Accessed January 17, 2018.
  150. Mennella JA, Yourshaw LM, Morgan LK. Breastfeeding and smoking: short-term effects on infant feeding and sleep. Pediatrics. 2007;120(3):497-502. doi:10.1542/peds.2007-0488
  151. Mennella JA, Beauchamp GK. Understanding the Origin of Flavor Preferences. Chem Senses. 2005;30(Suppl 1):i242-i243. doi:10.1093/chemse/bjh204
  152. Aligne CA, Moss ME, Auinger P, Weitzman M. Association of pediatric dental caries with passive smoking. JAMA. 2003;289(10):1258-1264.
  153. Leung GM, Ho L-M, Lam T-H. Secondhand smoke exposure, smoking hygiene, and hospitalization in the first 18 months of life. Arch Pediatr Adolesc Med. 2004;158(7):687-693. doi:10.1001/archpedi.158.7.687
  154. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The Changing Face of Heroin Use in the United States: A Retrospective Analysis of the Past 50 Years. JAMA Psychiatry. 2014;71(7):821-826. doi:10.1001/jamapsychiatry.2014.366
  155. Haas AL, Peters RH. Development of substance abuse problems among drug-involved offenders. Evidence for the telescoping effect. J Subst Abuse. 2000;12(3):241-253.
  156. Ehlers CL, Gizer IR, Vieten C, et al. Cannabis dependence in the San Francisco Family Study: age of onset of use, DSM-IV symptoms, withdrawal, and heritability. Addict Behav. 2010;35(2):102-110. doi:10.1016/j.addbeh.2009.09.009
  157. Mann K, Ackermann K, Croissant B, Mundle G, Nakovics H, Diehl A. Neuroimaging of gender differences in alcohol dependence: are women more vulnerable? Alcohol Clin Exp Res. 2005;29(5):896-901.
  158. Randall CL, Roberts JS, Del Boca FK, Carroll KM, Connors GJ, Mattson ME. Telescoping of landmark events associated with drinking: a gender comparison. J Stud Alcohol. 1999;60(2):252-260.
  159. Greenfield SF, Back SE, Lawson K, Brady KT. Substance abuse in women. Psychiatr Clin North Am. 2010;33(2):339-355. doi:10.1016/j.psc.2010.01.004
  160. Perkins KA, Scott J. Sex differences in long-term smoking cessation rates due to nicotine patch. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2008;10(7):1245-1250. doi:10.1080/14622200802097506
  161. Langdon KJ, Leventhal AM, Stewart S, Rosenfield D, Steeves D, Zvolensky MJ. Anhedonia and anxiety sensitivity: prospective relationships to nicotine withdrawal symptoms during smoking cessation. J Stud Alcohol Drugs. 2013;74(3):469-478.
  162. Franklin TR, Napier K, Ehrman R, Gariti P, O’Brien CP, Childress AR. Retrospective study: influence of menstrual cycle on cue-induced cigarette craving. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2004;6(1):171-175. doi:10.1080/14622200310001656984
  163. Weinberger AH, Smith PH, Allen SS, et al. Systematic and meta-analytic review of research examining the impact of menstrual cycle phase and ovarian hormones on smoking and cessation. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2015;17(4):407-421. doi:10.1093/ntr/ntu249
  164. Tobacco Research and Intervention Program. Forever Free: A Guide To Remaining Smoke Free. Booklet 3: Smoking And Weight. Tampa, FL: H. Lee Moffitt Cancer Center & Research Institute, University of South Florida; 2000.
  165. National Institutes of Health (NIH). Quitting Smoking Benefits Health Despite Weight Gain. National Institutes of Health (NIH). Published March 25, 2013. Accessed January 19, 2018.
  166. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331. doi:10.1056/NEJMoa1005359
  167. Center for Substance Abuse Treatment. Substance Abuse Treatment: Addressing the Specific Needs of Women. Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2009. Accessed January 3, 2018.
  168. Chen X, Burgdorf K, Dowell K, Roberts T, Porowski A, Herrell JM. Factors associated with retention of drug abusing women in long-term residential treatment. Eval Program Plann. 2004;27(2):205-212. doi:10.1016/j.evalprogplan.2004.01.010
  169. McMurtrie C, Rosenberg KD, Kerker BD, Kan J, Graham EH. A unique drug treatment program for pregnant and postpartum substance-using women in New York City: results of a pilot project, 1990-1995. Am J Drug Alcohol Abuse. 1999;25(4):701-713.
  170. Volpicelli JR, Markman I, Monterosso J, Filing J, O’Brien CP. Psychosocially enhanced treatment for cocaine-dependent mothers: evidence of efficacy. J Subst Abuse Treat. 2000;18(1):41-49.
  171. Meyer MC, Johnston AM, Crocker AM, Heil SH. Methadone and buprenorphine for opioid dependence during pregnancy: a retrospective cohort study. J Addict Med. 2015;9(2):81-86. doi:10.1097/ADM.0000000000000092
  172. National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition). Bethesda, MD: National Institutes of Health; 2012. Accessed January 31, 2018.
  173. LACTMED: Buprenorphine. TOXNET Toxicology Data Network. Bethesda, MD: U.S. National Library of Medicine; 2018.
  174. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence syndrome. Addict Abingdon Engl. 2011;106(3):574-580. doi:10.1111/j.1360-0443.2010.03170.x
  175. Kraft WK, Adeniyi-Jones SC, Chervoneva I, et al. Buprenorphine for the Treatment of the Neonatal Abstinence Syndrome. N Engl J Med. 2017;376(24):2341-2348. doi:10.1056/NEJMoa1614835
  176. National Institute on Mental Health (NIMH). Depression. Published 2016. Accessed January 4, 2018.
  177. National Institute of Mental Health (NIMH). Anxiety Disorders. Bethesda, MD: National Institutes of Health; 2009.
  178. National Institute of Mental Health (NIMH). Eating Disorders: About More Than Food. Bethesda, MD: National Institutes of Health; 2018. Accessed January 31, 2018.
  179. Annis HM, Graham JM. Profile types on the Inventory of Drinking Situations: implications for relapse prevention counseling. Psychol Addict Behav. 1995;9(3):176-182.
  180. Perkins KA, Giedgowd GE, Karelitz JL, Conklin CA, Lerman C. Smoking in Response to Negative Mood in Men Versus Women as a Function of Distress Tolerance. Nicotine Tob Res. 2012;14(12):1418-1425. doi:10.1093/ntr/nts075
  181. Shen W, Liu Y, Li L, Zhang Y, Zhou W. Negative moods correlate with craving in female methamphetamine users enrolled in compulsory detoxification. Subst Abuse Treat Prev Policy. 2012;7:44. doi:10.1186/1747-597X-7-44
  182. de Boinville M. Office of The Assistant Secretary for Planning and Evaluation. ASPE Policy Brief: Screening for Domestic Violence in Health Care Settings. Washington, DC: U.S. Department of Health and Human Services; 2013.
  183. U.S. Department of Health and Human Services (HHS). 2013 Trans-HHS Intimate Partner Violence Screening and Counseling: Research Symposium. Published October 5, 2015. Accessed January 24, 2018.
  184. Factsheet: The Violence Against Women Act. The White House Accessed January 24, 2018.
  185. Reauthorizing the Violence Against Women Act: Key Provisions in S. 47. The White House Accessed January 24, 2018.
  186. National Institutes of Health (NIH). Report: Intimate Partner Violence Screening and Counseling Research Symposium.; 2013. Accessed January 24, 2018.
  187. National Bioethics Advisory Commission -- Publications. Published 2001. Accessed January 24, 2018.
  188. ORWH. Office of Research on Women’s Health. Accessed February 1, 2018.
  189. Whitten L. NIDA Notes: Women and Sex/Gender Differences Research Program. Published April 19, 2012. Accessed January 24, 2018.
  190. Committee on Obstetric Practice. Committee Opinion No. 722: Marijuana use during 118 pregnancy and lactation. Obstet Gynecol. 2017;130 (4):e205-e209.
  191. Study finds increased cannabis use during pregnancy - Self-reported medical and nonmedical cannabis use among pregnant women in the United States, JAMA Published online June 18, 2019.